CELL & GENE THERAPY PRODUCTS 2025

MANUFACTURING, QUALITY AND REGULATORY CONSIDERATIONS

KNOWLEDGE SHARING AND **CAPACITY BUILDING**

- The ***revolutionary n=1 gene therapy is an exemplary collaboration*** between academia, industry, regulators, and the hospital to deliver a groundbreaking therapy.
- Gene editing, epi editing, and stem cell therapies continue to ***progress toward later stages***.
- The ***FDA Start Pilot Program continues to blaze the path for rare diseases***, with effective partnerships between sponsors and the FDA as they bring therapies for two rare diseases with unmet need – ***Rett Syndrome*** and ***NGLY1 deficiency***.
- ***Driving sustainability in CGT development and commercialization*** continues to be a prominent topic.

CELL & GENE THERAPY PRODUCTS 2025 **BY THE NUMBERS**

First-Time Attendees

144

Regulators Participated

11

Company Participation

104

Country Participation

17

Austria | Belgium | Canada | China | Denmark | France | Germany | Italy | Japan | Netherlands | Saudi Arabia | South Korea | Spain | Sweden | Taiwan | United Kingdom | United States

CASSS RESOURCES

Looking for more past meeting content?

Speaker slides, roundtable notes, and video presentations can be accessed through **Papers and Presentations** and **CASSS On Demand** on our website. **www.casss.org**

CASSS™
SHARING SCIENCE **SOLUTIONS**